Lower-Dose DMPA

Description: A single subcutaneous injection of medroxyprogesterone acetate injectable suspension, (dose between 45mg - 105mg), currently approved for intramusclar use, given every 3 months.

Product Details

User: Female

Hormonal: Yes

Delivery Method: Injectable

Duration Type: Short-acting

Duration: 3 months plus at least 1 month grace period

Regimen:
  • a single subcutaneous injection once every 3 months

Dose: TBD between 45mg -105mg

Active Pharmaceutical Ingredient (API):
  • medroxyprogesterone acetate

Inactive material: polyethylene glycol 3350; polysorbate 80; sodium chloride; methylparaben; propylparaben; water for injection

Multipurpose Preventive Technology (MPT): No

Status Details

Developer: FHI 360

Project Phase: Pre-Clinical and Clinical Development

Development Stage: Phase I

Began discovery in: 2013

Active Development: Yes

Status Details:
  • Phase I study ongoing.

Additional Information

References:
  • Shelton JD, Halpern V. (2014) Subcutaneous DMPA: a better lower dose approach. Contraception. 89(5):341-3.

Vertical Tabs

Print